Valproic Acid in Women of Reproductive Potential: What Clinicians Need to Know

Valproic acid remains one of the clearest examples in psychopharmacology of a medication whose reproductive risks must shape prescribing decisions well before pregnancy occurs. In her video overview, Marlene Freeman, MD, emphasizes that clinicians who treat girls and women of reproductive potential should assume that pregnancy is always clinically relevant, regardless of a patient’s current reproductive plans. Many pregnancies are unplanned, and for patients with chronic or recurrent psychiatric illness, a medication selected today may still be part of long-term treatment when pregnancy becomes a possibility.

For that reason, Dr. Freeman argues that treatment choices should favor medications that can be more reasonably continued if pregnancy occurs. Valproic acid is a major exception. As she explains, it is associated with a high risk of major congenital malformations, including neural tube defects, as well as longer-term neurodevelopmental harms after in utero exposure. These risks begin early, often before pregnancy is recognized, which makes later intervention insufficient as a safety strategy. In practical terms, this means valproic acid should not be viewed as acceptable simply because a patient is using contraception or is not currently planning pregnancy.

The featured JCP articles reinforce this message from several angles. Dr. Freeman’s editorial takes the strongest position, arguing that valproic acid should be taken off the table for women of reproductive potential altogether. A separate commentary considers whether additional regulatory safeguards, including a REMS-style framework, could reduce fetal exposure through more structured monitoring and documentation. Meanwhile, new US data show that valproic acid continues to be prescribed to females of reproductive age, often without documented contraception, underscoring that awareness alone has not solved the problem.

Clinically, the takeaway is not only that valproic acid carries serious risk, but that prescribing decisions in psychiatry must account for reproductive safety as part of routine care. For some patients with severe or treatment-refractory illness, complex decisions may still arise. Even so, the current evidence suggests that clinicians should avoid initiating valproic acid in women of reproductive potential whenever possible and should recognize that preventing fetal exposure requires more than counseling alone. As the field continues to debate the role of system-level safeguards, this topic remains an important reminder that medication selection, patient education, and long-term treatment planning are inseparable in reproductive psychiatry.